Do we make progress in elderly patients with metastatic colorectal cancer?

References

• Papamichael D, Audisio RA, Glimelius B, et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol. 2015;26:463–476.
   PubMed Web of Science ®Google Scholar
• Aparicio T, Francois E, Cristol-Dalstein L, et al. PRODIGE 34-FFCD 1402-ADAGE: adjuvant chemotherapy in elderly patients with resected stage III colon cancer: a randomized phase 3 trial. Dig Liver Dis. 2016;48:206–207.
   PubMedGoogle Scholar
• Folprecht G, Seymour MT, Saltz L, et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol. 2008;26:1443–1451.
   PubMed Web of Science ®Google Scholar
• Jackson NA, Barrueco J, Soufi-Mahjoubi R, et al. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Cancer. 2009;115:2617–2629.
   PubMed Web of Science ®Google Scholar
• Venderbosch S, Doornebal J, Teerenstra S, et al. Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG). Acta Oncol. 2012;51:831–839.
   PubMed Web of Science ®Google Scholar
• Mitry E, Rougier P. Review article: benefits and risks of chemotherapy in elderly patients with metastatic colorectal cancer. Aliment Pharmacol Ther. 2009;29:161–171.
   PubMed Web of Science ®Google Scholar
• Lieu CH, Renfro LA, de Gramont A, et al. Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. J Clin Oncol. 2014;32:2975–2984.
   PubMed Web of Science ®Google Scholar
• Sorbye H, Pfeiffer P, Cavalli-Bjorkman N, et al. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer. 2009;115:4679–4687.
   PubMed Web of Science ®Google Scholar
• Mol L, Koopman M, van Gils CW, et al. Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands. Acta Oncol. 2013;52:950–955.
   PubMed Web of Science ®Google Scholar
• Cremolini C, Schirripa M, Antoniotti C, et al. First-line chemotherapy for mCRC – a review and evidence-based algorithm. Nat Rev Clin Oncol. 2015;12:607–619.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386–1422.
   PubMed Web of Science ®Google Scholar
• Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–1075.
   PubMed Web of Science ®Google Scholar
• Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA. 2017;317:2392–2401.
   PubMed Web of Science ®Google Scholar
• Doat S, Thiebaut A, Samson S, et al. Elderly patients with colorectal cancer: treatment modalities and survival in France. National data from the ThInDiT cohort study. Eur J Cancer. 2014;50:1276–1283.
   PubMed Web of Science ®Google Scholar
• Razenberg LG, Creemers GJ, Beerepoot LV, et al. Age-related systemic treatment and survival of patients with metachronous metastases from colorectal cancer. Acta Oncol. 2016;55:1443–1449.
   PubMed Web of Science ®Google Scholar
• Tomita Y, Karapetis CS, Ullah S, et al. Survival improvements associated with access to biological agents: results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry. Acta Oncol. 2016;55:480–485.
   PubMed Web of Science ®Google Scholar
• Braendegaard Winther S, Baatrup G, Pfeiffer P, et al. Trends in colorectal cancer in the elderly in Denmark, 1980-2012. Acta Oncol. 2016;55(Suppl 1):29–39.
   PubMed Web of Science ®Google Scholar
• Sorbye H, Cvancarova M, Qvortrup C, et al. Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. Ann Oncol. 2013;24:2354–2360.
   PubMed Web of Science ®Google Scholar
• Mitry E, Rollot F, Jooste V, et al. Improvement in survival of metastatic colorectal cancer: are the benefits of clinical trials reproduced in population-based studies? Eur J Cancer. 2013;49:2919–2925.
   PubMed Web of Science ®Google Scholar
• Tapia Rico G, Karapetis C, Townsend AR, et al. Do we know what to do with our nonagenarian and centenarian patients with metastatic colorectal cancer (mCRC)? Results from the South Australian mCRC registry. Acta Oncol. 2018;57:1455–1457. In this issue.
   Google Scholar
• Lund C, Vistisen K, Dehlendorff C, et al. Age-dependent differences in first-line chemotherapy in patients with metastatic colorectal cancer: the DISCO Study. Acta Oncol. 2018;57:1445–1454. In this issue.
   Google Scholar
• Prasanna T, Karapetis CS, Roder D, et al. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. Acta Oncol. 2018;57:1438–1444. In this issue.
   Google Scholar
• Patel SS, Nelson R, Sanchez J, et al. Elderly patients with colon cancer have unique tumor characteristics and poor survival. Cancer. 2013;119:739–747.
   PubMed Web of Science ®Google Scholar
• Weinberg BA, Poorman K, Arguello D, et al. Impact of patient age on molecular alterations in left-sided colorectal tumors. J Clin Oncol. 2017;35:3592. Abstract 3592.
   Web of Science ®Google Scholar
• Ahmed S, Pahwa P, Le D, et al. Primary tumor location and survival in the general population with metastatic colorectal cancer. Clin Colorectal Cancer. 2018;17:e201–e2e6.
   PubMed Web of Science ®Google Scholar
• Christensen TD, Palshof JA, Larsen FO, et al. Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer. Acta Oncol. 2018;57:1057–1062.
   PubMed Web of Science ®Google Scholar
• Hugen N, van de Velde CJ, de Wilt JH, et al. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol. 2014;25:651–657.
   PubMed Web of Science ®Google Scholar
• Sjoquist KM, Renfro LA, Simes RJ, et al. Personalizing survival predictions in advanced colorectal cancer: The ARCAD Nomogram Project. J Natl Cancer Inst. 2018;110:638–648.
   PubMedGoogle Scholar
• Tampellini M, Di Maio M, Baratelli C, et al. Treatment of patients with metastatic colorectal cancer in a real-world scenario: probability of receiving second and further lines of therapy and description of clinical benefit. Clin Colorectal Cancer. 2017;16:372–376.
   PubMed Web of Science ®Google Scholar
• Cavalli-Bjorkman N, Qvortrup C, Sebjornsen S, et al. Lower treatment intensity and poorer survival in metastatic colorectal cancer patients who live alone. Br J Cancer. 2012;107:189–194.
   PubMed Web of Science ®Google Scholar
• Winther SB, Skuladottir H, Hofsli E, et al. NORDIC9: a randomized phase II trial comparing first-line palliative full-dose monotherapy (S-1) with reduced dose combination therapy (SOx) in older and frail patients with metastatic colorectal cancer (mCRC). Ann Oncol. 2018;29(Suppl 8): abstract 455PD.
   Google Scholar
• Winther SB, Zubcevic K, Qvortrup C, et al. Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review. Acta Oncol. 2016;55:881–885.
   PubMed Web of Science ®Google Scholar
• Kwakman JJM, Simkens LHJ, van Rooijen JM, et al. Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. Ann Oncol. 2017;28:1288–1293.
   PubMed Web of Science ®Google Scholar
• Biganzoli L, Lichtman S, Michel JP, et al. Oral single-agent chemotherapy in older patients with solid tumours: a position paper from the International Society of Geriatric Oncology (SIOG). Eur J Cancer. 2015;51:2491–2500.
   PubMed Web of Science ®Google Scholar
• Butzke B, Oduncu FS, Severin F, et al. The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance. Acta Oncol. 2016;55:318–328.
   PubMed Web of Science ®Google Scholar
• Hammerman A, Greenberg-Dotan S, Battat E, et al. The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study. Acta Oncol. 2015;54:164–170.
   PubMed Web of Science ®Google Scholar
• Stein A, Petersen V, Schulze M, et al. Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study. Acta Oncol. 2015;54:171–178.
   PubMed Web of Science ®Google Scholar
• Nygren P. Always look at the bright side of drugs? Acta Oncol. 2015;54:145–147.
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23:3706–3712.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14:1077–1085.
   PubMed Web of Science ®Google Scholar
• Tebbutt NC, Wilson K, Gebski VJ, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol. 2010;28:3191–3198.
   PubMed Web of Science ®Google Scholar
• Pinto C, Antonuzzo L, Porcu L, et al. Efficacy and safety of bevacizumab combined with fluoropyrimidine monotherapy for unfit or older patients with metastatic colorectal cancer: a systematic review and meta-analysis. Clin Colorectal Cancer. 2017;16:e61–e72.
   PubMed Web of Science ®Google Scholar
• Koch C, Schwing AM, Herrmann E, et al. Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis. Oncotarget. 2018;9:10272–10283.
   PubMedGoogle Scholar
• Landre T, Maillard E, Taleb C, et al. Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients. Int J Colorectal Dis. 2018;33:1125–1130.
   PubMed Web of Science ®Google Scholar
• Aparicio T, Bouche O, Taieb J, et al. Bevacizumab + chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results. Ann Oncol. 2018;29:127–132.
   PubMedGoogle Scholar
• Aparicio T, Lavau-Denes S, Phelip JM, et al. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). Ann Oncol. 2016;27:121–127.
   PubMed Web of Science ®Google Scholar
• Seymour MT, Thompson LC, Wasan HS, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011;377:1749–1759.
   PubMed Web of Science ®Google Scholar
• Jafari M, Tessier W, El Hajbi F, et al. Delayed anastomotic leakage following bevacizumab administration in colorectal cancer patients. Acta Oncol. 2016;55:1250–1252.
   PubMed Web of Science ®Google Scholar
• Bergamo F, Lonardi S, Salmaso B, et al. Angiogenesis inhibitors and symptomatic anal ulcers in metastatic colorectal cancer patients. Acta Oncol. 2018;57:412–419.
   PubMed Web of Science ®Google Scholar
• Weickhardt AJ, Williams DS, Lee CK, et al. Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. Br J Cancer. 2015;113:37–45.
   PubMed Web of Science ®Google Scholar
• Hagman H, Bendahl PO, Melander O, et al. Vasoactive peptides associate with treatment outcome of bevacizumab-containing therapy in metastatic colorectal cancer. Acta Oncol. 2017;56:653–660.
   PubMed Web of Science ®Google Scholar
• van Dijk E, Biesma HD, Cordes M, et al. Loss of chromosome 18q11.2-q12.1 is predictive for survival in patients with metastatic colorectal cancer treated with bevacizumab. J Clin Oncol. 2018;36:2052–2060.
   PubMed Web of Science ®Google Scholar
• Punt CJA, Huiskens J, van Gulik T, et al. Pseudoprogression on bevacizumab treatment: tumor-dynamics in the modern era of systemic treatment for metastatic colorectal cancer. Acta Oncol. 2018;57:681–682.
   PubMed Web of Science ®Google Scholar
• Hermunen K, Lantto E, Poussa T, et al. Can carcinoembryonic antigen replace computed tomography in response evaluation of metastatic colorectal cancer? Acta Oncol. 2018;57:750–758.
   PubMed Web of Science ®Google Scholar
• Tamburini E, Rudnas B, Santelmo C, et al. Maintenance based bevacizumab versus complete stop or continuous therapy after induction therapy in first line treatment of stage IV colorectal cancer: a meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2016;104:115–123.
   PubMed Web of Science ®Google Scholar
• Goey KKH, Elias SG, Hinke A, et al. Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials. Br J Cancer. 2017;117:1768–1776.
   PubMed Web of Science ®Google Scholar
• Aparicio T, Ghiringhelli F, Boige V, et al. Bevacizumab maintenance versus no maintenance during chemotherapy-free intervals in metastatic colorectal cancer: a randomized phase III trial (PRODIGE 9). J Clin Oncol. 2018;36:674–681.
   PubMedGoogle Scholar
• Aaldriks AA, Maartense E, Nortier HJ, et al. Prognostic factors for the feasibility of chemotherapy and the Geriatric Prognostic Index (GPI) as risk profile for mortality before chemotherapy in the elderly. Acta Oncol. 2016;55:15–23.
   PubMed Web of Science ®Google Scholar
• Jorgensen TL, Pfeiffer P. It's time to move forward in geriatric oncology. Acta Oncol. 2016;55:1–2.
   Web of Science ®Google Scholar
• Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018;36:2326–2347.
   PubMed Web of Science ®Google Scholar
• Aparicio T, Gargot D, Teillet L, et al. Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients. Eur J Cancer. 2017;74:98–108.
   PubMed Web of Science ®Google Scholar
• Aparicio T, Bouche O, Francois E, et al. Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer. Eur J Cancer. 2018;97:16–24.
   PubMed Web of Science ®Google Scholar
• Rosati G, Cordio S, Bordonaro R, et al. Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. Ann Oncol. 2010;21:781–786.
   PubMed Web of Science ®Google Scholar